14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

BTIG analyst Justin Zelin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Target of $90.

Stifel analyst Ben Burnett initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Target of $86.

Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight.

HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price target.

HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price target.

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.23) by 16.26 percent. This is a 35.63 percent increase over losses of $(1.60) per share from the same period last year.

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

S-8 POS - Jasper Therapeutics, Inc. (0001788028) (Filer)

S-8 POS - Jasper Therapeutics, Inc. (0001788028) (Filer)

S-8 POS - Jasper Therapeutics, Inc. (0001788028) (Filer)

S-8 - Jasper Therapeutics, Inc. (0001788028) (Filer)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13D/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences: Stifel 2024 Healthcare ConferenceConference Dates: November 18 – 19, 2024Presentation Date: Monday, November 18, 2024, 9:45 a.m. ETPresentation Format: Fireside Chat Jefferies London Healthcare Conference 2024Conference Dates: November 19-21, 2024 7th

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy clinical study in lower-risk myelodysplastic syndromes (LR-MDS). "We achieved several significant milestones in our mast cell development programs in recent months, highlighted by positive

REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts. "We are pleased to present promising preclinical results from multiple studies at ACAAI this year," said Wendy Pan

REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow up period. Additionally, Jasper also announced it has obtained regulatory clearance in the US and in the EU to further expand the BEACON s

14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci

REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that Health Canada has cleared the Company's Clinical Trial Application (CTA) for a Phase 1b/2a asthma challenge study evaluating briquilimab in asthma. "We are excited to announce that Health Canada has issued a no objection letter allowing us to move forward with our first clinical trial evaluating briquilimab in

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Conference Dates: September 9-11, 2024Presentation Date/Time: Tuesday, September 10, 2024, 3:00 p.m. ETPresentation Format: Fireside Chat 2024 Cantor Fitzgerald Healthcare ConferenceConference Date

Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to BEACON study Initial data from BEACON study through 240mg dosing cohort to be presented in 4Q24 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced results for the fiscal qua

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced today announced that its management will present at the Oppenheimer Novel Targets in Immunology Summit, to be held on Monday, June 24, 2024, in New York City. Oppenheimer Novel Targets in Immunology Summit Presentation Date/Time: Monday, June 24, 2024; 11:45 a.m. EDTPresentation Format: Panel Discussion – "Novel Immunological Mecha

JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00

BTIG Research initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $90.00

Stifel initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $86.00

H.C. Wainwright initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $65.00

Evercore ISI initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $65.00

RBC Capital Mkts initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $70.00

TD Cowen initiated coverage of Jasper Therapeutics with a rating of Outperform

CapitalOne initiated coverage of Jasper Therapeutics with a rating of Overweight and set a new price target of $7.00

Cantor Fitzgerald initiated coverage of Jasper Therapeutics with a rating of Overweight and set a new price target of $10.00

Credit Suisse reiterated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board and as Senior Clinical Advisor REDWOOD CITY, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Edwin J. Tucker as Jasper's Chief Medical Officer. Concurr

REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Stephen J. Galli, Professor of Pathology, Microbiology and Immunology, and the Mary Hewitt Loveless, M.D. Professor at Stanford Medicine, to the company's Scientific Advisory Board. "We are thrilled to welcome Dr. Galli to our Scientific Advisory Board," said Ron

REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Company's Senior Vice President, Development Operations. "We are pleased to welcome David to our team. His outstanding track record in setting strategic directions for clinical research and operations will allow us to effectively advance our dev

REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Daniel Adelman, M.D., as the company's Acting Chief Medical Officer. Dr. Adelman is a highly experienced clinical leader and innovator and brings to Jasper more than 30 years of experience in the clinical development of novel therapies for immunologic diseases at Ai

REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update. Highlights for Recent Weeks: Phase 1b data for JSP191 in the treatment of patients with MDS or AML accepted for presentation as a late breaking oral abstract at the Tandem Meetings of ASTCT and CIBMTR on April 26th, 2022. Data from 17 patients show JSP191, in combination with low dose radiation and fludarabine conditioning, was well tolerated in patients 62 to 79 years old with no JSP191-related se

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment of Ronald Martell as the company's Chief Executive Officer effective March 15, 2022. "Ron is an experienced CEO with a proven track record of leading public biopharmaceutical companies in all phases of development, and we are pleased to welcome him as the Jasper CEO to lead the company through the next stage of growth and success," said Bill Lis, Chairman of Jasper Therapeutics. "Ron brings to Jasper a depth of experience in oncology and cell therapy development and commercialization, as